Suppr超能文献

一些2,3-二取代-4(3H)-喹唑啉酮衍生物的合成及其抗利什曼原虫活性评价

Synthesis and antileishmanial evaluation of some 2,3-disubstituted-4(3H)-quinazolinone derivatives.

作者信息

Birhan Yihenew Simegniew, Bekhit Adnan Ahmed, Hymete Ariaya

机构信息

Department of Chemistry, Natural and Computational Science College, Debre Markos University, Debre Markos, Ethiopia.

Department of Pharmaceutical Chemistry, Alexandria University, Alexandria, 21215, Egypt.

出版信息

Org Med Chem Lett. 2014 Dec;4(1):10. doi: 10.1186/s13588-014-0010-1. Epub 2014 Sep 17.

Abstract

BACKGROUND

Leishmaniasis is a neglected tropical parasitic diseases affecting millions of people around the globe. Quinazolines are a group of compounds with diverse pharmacological activities. Owing to their promising antileishmanial activities, some 3-aryl-2-(substitutedstyryl)-4(3H)-quinazolinones were synthesized in good yields (65.2% to 86.4%).

RESULTS

The target compounds were synthesized by using cyclization, condensation, and hydrolysis reactions. The structures of the synthesized compounds were determined using elemental microanalysis, infrared (IR), and proton nuclear magnetic resonance ((1)H NMR). The in vitro antileishmanial activities of the synthesized compounds were evaluated using Leishmania donovani strain. All the synthesized compounds displayed appreciable antileishmanial activities (IC50 values, 0.0128 to 3.1085 μg/ml) as compared to the standard drug miltefosine (IC50 = 3.1911 μg/ml). (E)-2-(4-chlorostyryl)-3-p-tolyl-4(3H)-quinazolinone (7) is the compound with the most promising antileishmanial activities (IC50 = 0.0128 μg/ml) which is approximately 4 and 250 times more active than the standard drugs amphotericin B deoxycholate (IC50 = 0.0460 μg/ml) and miltefosine (IC50 = 3.1911 μg/ml), respectively.

CONCLUSIONS

The results obtained from this investigation indicate that the synthesized and biologically evaluated quinazoline compounds showed promising antileishmanial activities and are good scaffolds for the synthesis of different antileishmanial agents.

摘要

背景

利什曼病是一种被忽视的热带寄生虫病,影响着全球数百万人。喹唑啉是一类具有多种药理活性的化合物。由于其有前景的抗利什曼活性,合成了一些产率良好(65.2%至86.4%)的3-芳基-2-(取代苯乙烯基)-4(3H)-喹唑啉酮。

结果

通过环化、缩合和水解反应合成了目标化合物。使用元素微量分析、红外光谱(IR)和质子核磁共振(¹H NMR)确定了合成化合物的结构。使用杜氏利什曼原虫菌株评估了合成化合物的体外抗利什曼活性。与标准药物米替福新(IC50 = 3.1911 μg/ml)相比,所有合成化合物均表现出可观的抗利什曼活性(IC50值为0.0128至3.1085 μg/ml)。(E)-2-(4-氯苯乙烯基)-3-对甲苯基-4(3H)-喹唑啉酮(7)是具有最有前景抗利什曼活性的化合物(IC50 = 0.0128 μg/ml),其活性分别比标准药物两性霉素B脱氧胆酸盐(IC50 = 0.0460 μg/ml)和米替福新(IC50 = 3.1911 μg/ml)高约4倍和250倍。

结论

本研究获得的结果表明,合成并经生物学评估的喹唑啉化合物显示出有前景的抗利什曼活性,是合成不同抗利什曼药物的良好骨架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f132/4970432/bf90c0e4257d/13588_2014_Article_10_Sch1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验